{
  "cik": 1868279,
  "cik_padded": "0001868279",
  "entityName": "ArriVent BioPharma, Inc.",
  "fiscal_years": [
    {
      "accn": "0001104659-26-024127",
      "filed": "2026-03-05",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "cash": 45540000.0,
        "eps_diluted": -4.32,
        "net_income": -166308000.0,
        "operating_cash_flow": -160588000.0,
        "operating_income": -177534000.0,
        "stockholders_equity": 307224000.0,
        "total_assets": 333169000.0,
        "total_liabilities": 25945000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.08444978256907013,
        "roa_avg2y": -0.5469659322064557,
        "roa_period_end": -0.4991700908547914,
        "roe_avg2y": -0.5888280301233186,
        "roe_period_end": -0.5413248964924615
      }
    },
    {
      "accn": "0001104659-26-024127",
      "filed": "2026-03-05",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "cash": 74293000.0,
        "eps_diluted": -2.56,
        "net_income": -80488000.0,
        "operating_cash_flow": -70212000.0,
        "operating_income": -94308000.0,
        "stockholders_equity": 257654000.0,
        "total_assets": 274942000.0,
        "total_liabilities": 17288000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.06709773572310153,
        "roa_avg2y": -0.36749155328280525,
        "roa_period_end": -0.29274537902539444,
        "roe_avg2y": -1.5410153071481223,
        "roe_period_end": -0.31238793110139956
      }
    },
    {
      "accn": "0001104659-26-024127",
      "filed": "2026-03-05",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "cash": 150389000.0,
        "eps_diluted": -32.38,
        "net_income": -69333000.0,
        "operating_cash_flow": -55842000.0,
        "operating_income": -74590000.0,
        "stockholders_equity": -153193000.0,
        "total_assets": 163098000.0,
        "total_liabilities": 11801000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -0.4251002464775779,
        "roe_avg2y": 0.5818918850869904
      }
    },
    {
      "accn": "0001558370-25-001999",
      "filed": "2025-03-03",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -85109000.0
      },
      "period_end": "2022-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001104659-26-024127",
    "filed": "2026-03-05",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001868279.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001868279.json"
  },
  "ticker": "AVBP"
}